Imaging equipment

CE Mark for Faxitron Path+ Specimen Radiography System

Hologic, Inc. has announced it has CE Mark for the Faxitron Path+ Specimen Radiography System, the latest addition to the company’s growing portfolio of digital specimen radiography solutions.

Photo
Hologic's Faxitron Path+ Specimen Radiography System
Source: Hologic

The system features a superior, high-resolution imaging detector which enables pathologists to image a wide range of specimens of varying sizes, including bone, foetal remains and breast tissue directly in the lab. By combining a larger field of view with intuitive, easy-to-use software, the system provides pathologists with accurate results in an efficient manner. Additionally, the clear specimen images produced enable pathologists to satisfy the regulatory demands for De-Calcification End Point testing. Improving workflow within hospitals, clinicians can access the information they need to diagnose and treat their patients sooner.

The Faxitron Path+ system provides up to 10x geometric magnification, enabling imaging of small microcalcifications and ensuring accurate diagnoses. Optimal x-ray exposure settings can be selected regardless of specimen makeup and density to ensure the highest image quality is maintained. These features offer pathologists more versatile imaging options and help to reduce the Turn Around Time (TAT) for reports, meaning patients can receive their diagnoses more quickly.

Recommended article

Photo

Breast and skeletal health

AI is proving pivotal in women’s health solutions

Pete Valenti, Hologic’s division president of breast and skeletal health solutions, talks about how AI is driving innovation in breast health technology. Underpinning that evolution more recently has been the acquisition of two organisations – digital specimen radiography specialists Faxitron Bioptics and BioZorb marker manufacturer Focal Therapeutics.

As a world leader in mammography, Hologic has expanded its business over the past several years to make a meaningful and positive impact on breast health at each step of a patient’s journey, from screening to pathology. The Faxitron Path+ system is one of several innovative products that have been added to Hologic’s portfolio of breast health solutions following its acquisition of Faxitron Bioptics, a longstanding leader in digital specimen radiography.


Source: Hologic

18.11.2020

Read all latest stories

Related articles

Photo

Breast cancer backlog

Getting cancer screening programmes back on track with AI and digitisation

The Covid-19 pandemic continues to impact people’s health across the world. This goes beyond the disease itself, as healthcare systems adapt how they provide services. Routine screening has been…

Photo

Mammography

Advancing the Breast Continuum of Care

The pandemic has presented healthcare systems with new challenges, resulting in backlogs of routine screenings and delayed procedures which threaten the health and wellbeing of patients, as well as…

Photo

Covid-19's impact

Awareness is key for breast screening services

The impact of Covid-19 has been devastating; countless lives lost, millions of infections worldwide, health systems overwhelmed and economies rapidly shrinking. Screening, such as for breast or…

Related products

Hologic – 3Dimensions

Tomosynthesis

Hologic – 3Dimensions

Hologic, Inc.
Hologic -3DQuorum

Artificial Intelligence

Hologic -3DQuorum

Hologic, Inc.
Subscribe to Newsletter